OSE Immunotherapeutics Receives the EuroNext Tech40 Label

NEXT STORY
Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress
PREV STORY
Shire plc : Holding(s) in Company
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK

author_avatar
NASDAQ Market News

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

author_avatar
NASDAQ Market News

Biomaterials Market to Exhibit 12.2% CAGR and Hit USD 245.6 Billion still 2027; Increasing Number of Novel Product Launches to Skyrocket Demand: Fortune Business Insights™

author_avatar
NASDAQ Market News